Equities Analysts Offer Predictions for AXSM FY2025 Earnings

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Research analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Axsome Therapeutics in a report issued on Tuesday, February 11th. Cantor Fitzgerald analyst C. Duncan anticipates that the company will post earnings per share of ($2.88) for the year. Cantor Fitzgerald has a “Overweight” rating and a $121.00 price target on the stock. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($4.70) per share.

Several other equities analysts have also weighed in on the stock. Robert W. Baird increased their price objective on shares of Axsome Therapeutics from $112.00 to $116.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. Wells Fargo & Company increased their price target on shares of Axsome Therapeutics from $140.00 to $160.00 and gave the company an “overweight” rating in a report on Wednesday. StockNews.com upgraded Axsome Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. Leerink Partners increased their target price on Axsome Therapeutics from $110.00 to $150.00 and gave the stock an “outperform” rating in a research note on Monday. Finally, HC Wainwright restated a “buy” rating and issued a $190.00 price target on shares of Axsome Therapeutics in a research note on Tuesday. One analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. According to MarketBeat.com, Axsome Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $147.13.

Axsome Therapeutics Trading Down 0.5 %

Shares of Axsome Therapeutics stock opened at $131.55 on Thursday. The company has a quick ratio of 2.37, a current ratio of 2.44 and a debt-to-equity ratio of 1.97. The business has a fifty day simple moving average of $96.55 and a two-hundred day simple moving average of $92.67. Axsome Therapeutics has a 1 year low of $64.11 and a 1 year high of $134.18.

Axsome Therapeutics (NASDAQ:AXSM) last issued its earnings results on Tuesday, November 12th. The company reported ($1.34) EPS for the quarter, topping the consensus estimate of ($1.38) by $0.04. Axsome Therapeutics had a negative return on equity of 158.36% and a negative net margin of 91.87%. The company had revenue of $104.76 million during the quarter, compared to the consensus estimate of $98.71 million. During the same period in the previous year, the company posted ($1.32) EPS.

Hedge Funds Weigh In On Axsome Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in AXSM. JPMorgan Chase & Co. increased its stake in Axsome Therapeutics by 14.9% in the third quarter. JPMorgan Chase & Co. now owns 212,110 shares of the company’s stock valued at $19,062,000 after acquiring an additional 27,534 shares during the last quarter. Strategic Financial Concepts LLC bought a new position in shares of Axsome Therapeutics in the 4th quarter valued at $2,599,000. PDT Partners LLC bought a new position in shares of Axsome Therapeutics in the 3rd quarter valued at $1,052,000. Pallas Capital Advisors LLC acquired a new position in shares of Axsome Therapeutics during the 4th quarter worth $2,237,000. Finally, Captrust Financial Advisors bought a new stake in shares of Axsome Therapeutics during the 3rd quarter worth $514,000. 81.49% of the stock is currently owned by institutional investors and hedge funds.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.